Halda Therapeutics announces that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire Halda for $3.05 billion, payable in cash at closing, subject to customary adjustments. Halda’s portfolio includes HLD-0915, a first-in-class, oral RIPTAC™ therapeutic, in development for metastatic castration-resistant prostate cancer (mCRPC). Recently presented Phase 1/2 data demonstrated this novel therapy was well-tolerated and showed encouraging signs of anti-tumor activity, including reductions in prostate-specific antigen (PSA) and responses by Response Evaluation Criteria in Solid Tumors (RECIST), in patients with advanced prostate cancer.
Read the full article: Halda Therapeutics Announces Acquisition by Johnson & Johnson //
Source: https://www.globenewswire.com/news-release/2025/11/17/3189145/0/en/Halda-Therapeutics-Announces-Acquisition-by-Johnson-Johnson.html